8-K Announcements
6Material company update
Jan 2, 2026·SEC
Material company update
Nov 7, 2025·SEC
Material company update
Sep 5, 2025·SEC
Petros Pharmaceuticals, Inc.(PTPI)Earnings, Financials & Key Ratios
PTPI•NASDAQ
$0.01
Price updated Jun 27, 2026
AboutPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.Show more
- Revenue$0-100.0%
- EBITDA-$5M+68.5%
- Net Income$2M+113.4%
- EPS (Diluted)-1.56+53.3%
- ROE0.13%+100.0%
PTPI Price & Volume
Petros Pharmaceuticals, Inc. (PTPI) stock price & volume — 10-year historical chart
Loading chart...
Regulatory Pivot Masks Extreme Financial Data Anomalies
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Binary Regulatory Failure Risk
Key Thesis Takeaways
- Petros Pharmaceuticals is currently undergoing a high-stakes strategic transition to an OTC-focused business model, characterized by a complete cessation of commercial revenue since 2025Q1.
- The company faces significant binary regulatory risk regarding its primary therapeutic asset, compounded by extreme volatility in reported balance sheet figures that defy standard micro-cap valuation logic.
- Investors should exercise extreme caution given the persistent quarterly cash burn of $1.0M and the lack of a proven, sustainable path to profitability.
Verdict Logic
the company's equity position turned negative at -$9.6 million in 2025Q1, and the extreme discrepancy in reported cash levels suggests significant underlying financial reporting instability.
PTPI Growth Metrics
Petros Pharmaceuticals, Inc. (PTPI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM122.1%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM169.63%
Return on Capital
10 Years-73.94%
5 Years-80.67%
3 Years-94.27%
Last Year-0.32%
Peers Comparison
Key metrics vs top competitors for Petros Pharmaceuticals, Inc. (PTPI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.01 | $272.71K | -0.00 | -100% | — | 0.13% | — | |
| $9.95 | $1.38B | -0.97 | -2.75% | -43.5% | -50.65% | — | |
| $33.94 | $7.45B | 66.55 | 59% | -0.56% | -2.48% | — | |
| $4.14 | $1.28B | 207.00 | 22.23% | -6.63% | — | — | |
| $1206.51 | $1.14T | 52.57 | 44.7% | 34.98% | 101.17% | — | |
| $24.29 | $138.14B | 17.86 | -1.65% | 11.83% | 8.34% | — |
Compare PTPI vs Peers
Petros Pharmaceuticals, Inc. (PTPI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PTPI SEC Filings & Documents
Petros Pharmaceuticals, Inc. (PTPI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PTPI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PTPI Frequently Asked Questions
Petros Pharmaceuticals, Inc. (PTPI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
How fast is Petros Pharmaceuticals, Inc. growing?
Petros Pharmaceuticals, Inc. (PTPI) saw revenue decline by 100.0% over the past year.
Is PTPI profitable?
Yes, Petros Pharmaceuticals, Inc. (PTPI) is profitable, generating $3.2M in net income for fiscal year 2025.
Dividend & Returns
What is PTPI's return on equity?
Petros Pharmaceuticals, Inc. (PTPI) has a return on equity (ROE) of 0.1%. This is below average, suggesting room for improvement.
What is Petros Pharmaceuticals, Inc.'s free cash flow?
Petros Pharmaceuticals, Inc. (PTPI) had negative free cash flow of $5.9M in fiscal year 2025, likely due to heavy capital investments.